Current Research in Medical Sciences
ISSN 2958-0390
www.paradigmpress.org/crms
Volume 5 Number 2 March 2026

Activation of Prodrugs Depend on the Metabolism of These Prodrugs

Rezk R. Ayyad[1], Yasser Abdel Allem Hassan[2], Ahmed G. El-Dahshan[3], Mennah G. El-Dahshan[3], Sherif G. El-Dahshan[3] & Ahmed R. Ayyad[4]

[1] Pharmaceutical Medicinal Chemistry Department, Faculty of Pharmacy, Hilla University, Babylon, Iraq
[2] Pharmaceutics and Pharmaceutical Technology Department, Faculty of Pharmacy, Al-Kitab University, Kirkuk, Iraq
[3] Ministry of Health, Arab Republic of Egypt
[4] Faculty of Medicine, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
Correspondence: Rezk R. Ayyad, Pharmaceutical Medicinal Chemistry Department, Faculty of Pharmacy, Hilla University, Babylon, Iraq.

doi:10.63593/CRMS.2026.03.01

Abstract

Prodrugs depend on enzymatic processes, essentially in the liver, but can also occur in other tissues to release the active metabolite. These metabolic biotransformations are often enzymatically controlled, ensuring the drug becomes pharmacologically active at its site of action. Metabolism may occur at the target site (e.g., in viruses, where drugs are phosphorylated) or in the liver or other tissues. For example, codeine is activated by demethylation to morphine, which is a more active analgesic than codeine. Clopidogrel oxidized to 2-oxoclopidogrel which is active and 2-oxoclopidogrel which is metabolized in two active thiol metabolite. Enalapril is a prodrug that is metabolized to enalaprilat, the active form. L-Dopa is a prodrug that is converted into dopamine in the brain by decarboxylation. Azathioprine is metabolized to mercaptopurine, which is immunosuppressive. Sulfasalazine is a prodrug metabolized by azoreductase and converted to 5-aminosalicylic acid and sulfapyridine, which are more active than sulfasalazine. Prontosil is a prodrug converted into sulfanilamide, which is more active than prontosil. Salicin is a glycoside that is metabolized into salicylic acid, which is active as an analgesic. Valacyclovir is metabolized into acyclovir, which is an active antiviral.

Keywords: prodrugs, active drugs, metabolism, oxidation, hydrolysis, dealkylation

1. Introduction

Codeine is a narcotic drug when metabolized by dealkylation (demethylation), of codeine, which is used as antitussive more than analgesic when metabolized by oxidative dealkylation convert into morphine which used a narcotic analgesic more than codeine. This process activates the codeine by changing it into morphine and makes it more active than codeine.

Clopidogrel is a prodrug, meaning it is inactive needs to be metabolized into an active form to be effective, this process occur in the liver, where is

the clopidogrel oxidized in clopidogrel which further metabolized to the active thiol metabolite, this metabolite (thiol metabolite) binds to receptor on platelets which inhibit ADP from binding and preventing platelet aggregation.

Enalapril is a prodrug metabolized in the liver by its active form, enalaprilat, which is an ACE inhibitor that is currently available in USA. The metabolism occurs via cleavage of its ester group by the esterase enzyme and converts enalapril to enalaprilat, which is active as an ACE inhibitor.

Levodopa is a prodrug which is able to cross blood-brain barrier due to resemble amino acid; so penetrate to the brain, hence L-Dopa metabolized through several pathways, the decarboxylation it is the main process where L-Dopa convert to dopamine which is unable to cross the blood-brain barrier; so that L-Dopa which is prodrug is preferable to used in treatment of parkinsonism.

Azathioprine is an immunosuppressant that undergoes metabolism in the body through multiple pathways, primarily converting to 6-mercaptopurine, further metabolized by various enzymes into an active metabolite via the hypoxanthine phosphoribosyl transferase pathway, where 6-mercaptopurine is converted into its metabolite form 6-thioguanine nucleotide, which is incorporated into DNA and RNA, disrupting cellular processes and causing immunosuppression.

Sulfasalazine is a prodrug which used orally and inactive compound which is metabolized (hydrolyzed) in the intestine and convert into two active compounds (sulfapyridine) which is antibacterial and 5-amino salicylic acid which is anti-inflammatory, the 5-amino salicylic acid not absorbed from intestine and remain in the colon to treat the ulcerative colitis, in addition to antibacterial agent sulfapyridine.

Prontosil is the compound which is revolute the sulfa drugs era where it is a red dye act as a prodrug i.e. inactive invitro but in vivo metabolized where it reduced by reductase enzyme which result from intestinal flora and cleavage the prontosil into sulfanilamide which is active antibacterial and the first sulfa drug detected and try amino benzene, the other compound resulted from prontosil.

Salicin found in willow park is metabolized into salicylic acid and sugar part where the salicin is a glycoside (sugar part and non-sugar part), the salicylic acid is non-sugar part which has anti-inflammatory and analgesic properties, the cleavage of salicin in gastrointestinal tract and the salicylic acid is metabolized via bind with glycine and form salicyluric acid which is easily excreted, which easily detected in the urine.

Valacyclovir is a prodrug which converted to acyclovir and L-Valine through first pass intestinal and/or hepatic metabolism, acyclovir is the active drug which is also activated by phosphorylation to act as antiviral drug, and β-Lactamase inhibitors e.g., penicillins and cephalosporins, many of them are considered as prodrugs, e.g., ampicillin and amoxicillin, where the amino group of ampicillin may be metabolized via oxidative deamination and converted to benzylpenicillin (penicillin G). Also, amoxicillin, which has a phenolic OH and an amino group, may be converted to benzylpenicillin (penicillin G); hence, the metabolism of many drug derivatives may result in the lead drug of the class, e.g., penicillins and cephalosporins.

2. Pharmacology and Chemistry

(1) Codeine:



Codeine



Morphine

Codeine is an opioid compound used to relieve mild and moderate pain in people who suffer from moderate pain and know respond to non-steroidal anti-inflammatory drugs (NSAIDs). Codeine is used to relieve cough and has a moderate analgesic compared to morphine; so codeine is metabolized by oxidative dealkylation and converted to morphine, which has more analgesic activity than codeine.

(2) Clopidogrel:



Clopidogrel



Oxoclopidogrel

Clopidogrel is metabolized into oxoclopidogrel, which is active as an antiplatelet clopidogrel approved for managing unstable angina which may cause myocardial infarction (MI), where the oxoclopidogrel prevents platelet aggregation and inhibits clot formation. In addition, into the fibrinolytic of the oxoclopidogrel which is more active than clopidogrel.

(3) Enalapril:



Enalapril



Enalaprilat

Enalapril is an angiotensin-converting enzyme inhibitor (ACE I) which converts into enalaprilat, the active metabolite, which treat the hypertension via inhibit the vasoconstriction of blood vessels; hence increases the blood supply and oxygen to the heart.

(4) L-Dopa:



L-Dopa



Dopamine

L-Dopa used to treat the motor symptoms of Parkinson's disease, L-Dopa is similar to amino acids; hence carried by amino acid carrier and cross blood-brain barrier, dopamine is lipophilic more than L-Dopa and not cross the blood-brain barrier; so the L-Dopa metabolized in the brain by decarboxylase enzyme and converted to dopamine which treated the parkinsonism where helps to alleviate symptoms like tremor, stiffness, and slow movements and may treat encephalitis or brain injury which maybe cause parkinsonism.

(5) Azathioprine:



Azathioprine



6-Mercaptopurine

Azathioprine is an immunosuppressive after metabolized into 6-mercaptopurine. It is used to treat rheumatoid arthritis, and granulomatosis with polyangiitis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus (SLE) and in kidney transplant to prevent rejection; hence, as azathioprine is considered a prodrug needs to be metabolized to active 6-mercaptopurine.

(6) Sulfasalazine:



Sulfasalazine



Sulfapyridine



5-aminosalicylic acid

Sulfasalazine is a prodrug that needs to be cleaved between the two nitrogen to result in 5-aminosalicylic acid, which is anti-inflammatory and analgesic, and sulfapyridine, which is antibacterial.

Sulfasalazine is used in the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is also indicated for use in rheumatoid arthritis and used in other types of inflammatory arthritis, e.g., psoriatic arthritis and reactive arthritis; so the sulfasalazine inactive prodrug needs to be activated by metabolism to become active compounds.

(7) Prontosil:



Prontosil



Sulfanilamide



1,2,4-Triaminabenzene

Prontosil is sulfonamide antibacterial was one of the first effective drugs for treating bacterial infections caused by streptococci, it works by being converted in the body to sulfanilamide through metabolism by azoreductase enzyme; hence, sulfanilamide which resulted from prontosil inhibit the folic acid synthesize required for the growth and division of bacteria. Sulfanilamide was initially effective in puerperal fever and meningitis caused by meningococcus.

(8) Salicin:



Salicin



Salicylic acid

Salicin is a glycoside obtained from Salix, which is used in medicine for the relief of pain and inflammation, where it is precursor to salicylic acid, which is used in the treatment. Salicin is a prodrug that needs activation through cleavage of the glycosidic linkage between the glycone part and aglycon part, which is active, but salicin as is inactive. Salicin is used to reduce cartilage degeneration in osteoarthritis, potentially slowing disease progression the Salicylic acid also has a role in reducing the risk of cardiovascular diseases. Salicin has neuroprotective properties.

(9) Valacyclovir:



Valacyclovir



Acyclovir

Valacyclovir is a prodrug need to activate into an acyclovir through break valacyclovir into valine amino acid and acyclovir, which used in treatment of herpes virus infections including herpes labialis, also known as cold sores, herpes zoster also known as shingles, and herpes simplex also known as genital herpes in adults, it is also used to treat chicken pox and cold sores in children; hence valacyclovir is inactive when metabolized into acyclovir become active, further activated through phosphorylation.

(10) Ampicillin and amoxicillin:



Amoxicillin



Ampicillin



Benzylpenicillin

Ampicillin and amoxicillin are active prodrugs which are metabolized into benzylpenicillin become has longer duration (Ampicillin and Amoxicillin) more than benzylpenicillin, in this case the ampicillin and amoxicillin when metabolized retained with antibacterial properties, the penicillin used in treatment of a wide range of bacterial infection including those of the skin, throat, lungs and urinary tract maybe

used in treatment of pneumonia, air infections, dental abscesses and some sexually transmitted diseases (STD) in some cases penicillin can be uses to prevent rheumatic fever following streptococcal infection, the penicillins inhibit the cell wall of bacteria via inhibits the formation of peptidoglycan cross linkage; hence weakening the cell wall and cause bacterial rupture.

3. Conclusion

The pharmacological and biochemical significance of prodrugs, demonstrating how inactive or less active compounds are metabolically transformed into therapeutically active agents. Prodrugs such as codeine, clopidogrel, enalapril, levodopa, azathioprine, sulfasalazine, prontosil, salicin, valacyclovir, and certain β-lactam derivatives undergo specific metabolic pathways—oxidative dealkylation, enzymatic cleavage, reduction, phosphorylation, or ester hydrolysis—that enhance their bioavailability, selectivity, and therapeutic efficacy.

This metabolic activation allows for improved pharmacokinetics, targeted drug delivery, reduced adverse effects, and expanded clinical applications. Examples include levodopa's ability to cross the blood–brain barrier before conversion to dopamine for Parkinson's disease management, sulfasalazine's site-specific release of anti-inflammatory and antibacterial components in the colon, and clopidogrel's conversion to an active thiol metabolite for antiplatelet activity.

References

A Ibrahim, HM Sakr, RR Ayyad and MM Khalifa. (2022). Design, Synthesis, In-Vivo Anti-Diabetic Activity, In-Vitro α-Glucosidase Inhibitory Activity and Molecular Docking Studies of Some Quinazolinone Derivatives. *ChemistrySelect, 7*(14), e202104590.

AA El-Helby, MK Ibrahim, AA Abdel-Rahman, RRA Ayyad and MA Menshawy, et al. (2009). Synthesis, molecular modeling and anticonvulsant activity of benzoxazole derivatives. *Al-Azhar J Pharm Sci, 40*, 252-270.

AA Elhelby, RR Ayyad and MF Zayed. (2011). Synthesis and biological evaluation of some novel quinoxaline derivatives as anticonvulsant agents. *Arzneimittelforschung, 61*(07), 379-381.

AAM Abdel-Aziz, AS El-Azab, AM Alanazi, YA Asiri and IA Al-Suwaidan, et al. (2016). Synthesis and potential antitumor activity of 7-(4-substituted piperazin-1-yl)-4-oxoquinolines based on ciprofloxacin and norfloxacin scaffolds: in silico studies. *Journal of Enzyme Inhibition and Medicinal Chemistry, 31*(5), 796-809.

AGA El-Helby, H Sakr, RR Ayyad, HA Mahdy, MM Khalifa and A Belal, et al. (2022). Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors. *Bioorganic Chemistry, 103*, 104233.

AGA El-Helby, H Sakr, RRA Ayyad, K El-Adl, MM Ali and F Khedr. (2018). Design, synthesis, in vitro anti-cancer activity, ADMET profile and molecular docking of novel triazolo [3, 4-a] phthalazine derivatives targeting VEGFR-2 enzyme. *Anti-Cancer Agents in Medicinal Chemistry, 18*(8), 1184-1196.

AGA El-Helby, RR Ayyad, HM Sakr, AS Abdelrahim, K El-Adl, and FS Sherbiny, et al. (2017). Design, synthesis, molecular modeling and biological evaluation of novel 2, 3-dihydrophthalazine-1, 4-dione derivatives as potential anticonvulsant agents. *Journal of Molecular Structure, 1130*, 333-351.

AGA El-Helby, RRA Ayyad, H Sakr, K El-Adl, MM Ali and F Khedr. (2017). Design, synthesis, molecular docking, and anticancer activity of phthalazine derivatives as VEGFR-2 inhibitors. *Archiv der Pharmazie, 350*(12), 1700240.

AGA El-Helby, RRA Ayyad, K El-Adl and A Elwan. (2017). Quinoxalin-2(1H)-one derived AMPA-receptor antagonists: Design, synthesis, molecular docking and anticonvulsant activity. *Medicinal Chemistry Research, 26*, 2967-2984.

AGA El-Helby, RRA Ayyad, K El-Adl and H Elkady. (2018). Phthalazine-1, 4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking. *Molecular Diversity, 23*, 283-298.

AGA El-Helby, RRA Ayyad, K El-Adl, H Sakr, AA Abd-Elrahman and IH Eissa, et al. (2016). Design, molecular docking and synthesis of some novel 4-acetyl-1-substituted-3,4-

dihydroquinoxalin-2(1H)-one derivatives for anticonvulsant evaluation as AMPA-receptor antagonists. *Medicinal Chemistry Research, 25*, 3030-3046.

AGA El-Helby, RRA Ayyad, MF Zayed, HS Abulkhair, H Elkady and K El-Adl. (2019). Design, synthesis, in silico ADMET profile and GABA-A docking of novel phthalazines as potent anticonvulsants. *Archiv Der Pharmazie, 352*(5), 1800387.

AM Alaa, AS El-Azab, LA Abou-Zeid, KEH ElTahir and NI Abdel-Aziz, et al. (2016). Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5, 5-diphenylimidazolidine-2, 4-dione scaffold: molecular docking studies. *European Journal of Medicinal Chemistry, 115*, 121-131.

AM Alaa, LA Abou-Zeid, KEH ElTahir, RR Ayyad, AA Magda and AS El-Azab. (2016). Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibitory activities and molecular docking studies of substituted 2-mercapto-4(3H)-quinazolinones. *European Journal of Medicinal Chemistry, 121*, 410-421.

AM Alanazi, AAM Abdel-Aziz, TZ Shawer, RR Ayyad and AM Al-Obaid, et al. (2016). Synthesis, antitumor and antimicrobial activity of some new 6-methyl-3-phenyl-4(3H)-quinazolinone analogues: in silico studies. *Journal of Enzyme Inhibition and Medicinal Chemistry, 31*(5), 721-735.

AS El-Azab, AM Alaa, RR Ayyad, M Ceruso and CT Supuran. (2016). Inhibition of carbonic anhydrase isoforms I, II, IV, VII and XII with carboxylates and sulfonamides incorporating phthalimide/phthalic anhydride scaffolds. *Bioorganic & Medicinal Chemistry, 24*(1), 20-25.

Ayyad, Rezk R., et al. (2024). Overview on Some Drugs Act on DNA and RNA Other than Anti-Viral Drugs—The Direct Cholinomimetics and Cholinergic Blocking Agents Depend on Stereo Specificity of Cholinergic Receptors. *Current Research in Medical Sciences, 3*(3), 20-27.

Ayyad, Rezk R., et al. (2024). The Direct Cholinomimetics and Cholinergic Blocking Agents Depend on Stereo Specificity of Cholinergic Receptors. *Current Research in Medical Sciences, 3*(2), 1-7.

E Nassar, YA El-Badry, AMM Eltoukhy and RR Ayyad. (2016). Synthesis and Antiproliferative Activity of 1-(4-(1H-Indol-3-Yl)-6-(4-Methoxyphenyl) Pyrimidin-2-yl) Hydrazine and Its Pyrazolo Pyrimidine Derivatives. *Med Chem (Los Angeles), 6*, 224-233.

H M Sakr, R R Ayyad, K Mahmoud, A M Mansour and G Ahmed. (2021). Design, Synthesis of Analgesics and Anticancer of Some New Derivatives of Benzimidazole. *International Journal of Organic Chemistry, 11*(03), 144-169.

H Mahdy, M Shaat. (2022). Recent Advances in Drugs Targeting Protein Kinases for Cancer Therapy. *Al-Azhar Journal of Pharmaceutical Sciences, 66*(2), 56-86.

H Sakr, I Otify, RR Ayyad and A Elwan. (2023). **VEGFR-2** Inhibitors and Quinazoline-Based Anticancer Agents. *Al-Azhar Journal of Pharmaceutical Sciences, 68*(2), 111-129.

H Sakr, RR Ayyad, AA El-Helby, MM Khalifa and HA Mahdy. (2021). Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors. *Archiv der Pharmazie, 354*(6), 2000456.

IA Al-Suwaidan, AAM Abdel-Aziz, TZ Shawer, RR Ayyad and AM Alanazi, et al. (2015). Synthesis, antitumor activity and molecular docking study of some novel 3-benzyl-4 (3H) quinazolinone analogues. *Journal of Enzyme Inhibition and Medicinal Chemistry, 31*(1), 78-89.

IA Osman, RR Ayyad and HA Mahdy. (2022). New pyrimidine-5-carbonitrile derivatives as EGFR inhibitors with anticancer and apoptotic activities: design, molecular modeling and synthesis. *New Journal of Chemistry, 46*(24), 11812-11827.

IH Eissa, AM Metwaly, A Belal, ABM Mehany, RR Ayyad and K El-Adl, et al. (2019). Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors. *Archiv der Pharmazie, 352*(11), 1900123.

K El-Adl, AGA El-Helby, H Sakr, RR Ayyad, HA Mahdy and M Nasser, et al. (2020). Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro) benzylidene] thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. *Archiv der Pharmazie, 354*(2), 2000279.

K El-Adl, AGA El-Helby, RR Ayyad, HA Mahdy, MM Khalifa and HA Elnagar, et al. (2020). Design, synthesis, and anti-proliferative evaluation of new quinazolin-4 (3H)-ones as potential VEGFR-2 inhibitors. *Bioorganic & Medicinal Chemistry, 29*, 115872.

M Al Ward, AE Abdallah, M Zayed, R Ayyad and M El-Zahabi. (2024). New immunomodulatory anticancer quinazolinone based thalidomide analogs: Design, synthesis and biological evaluation. *Future Med Chem, 16*(23), 2523-2533.

M Salem, R Ayyad and H Sakr. (2022). Design and Synthesis of Some New Oxadiazole Derivatives as Anticancer Agents. *International Journal of Organic Chemistry, 12*(02), 64-74.

MA Mohamed, RR Ayyad, TZ Shawer, AM Alaa and AS El-Azab. (2016). Synthesis and antitumor evaluation of trimethoxyanilides based on 4 (3H)-quinazolinone scaffolds. *European Journal of Medicinal Chemistry, 112*, 106-113.

MF Zayed, RR Ayyad. (2012). Some novel anticonvulsant agents derived from phthalazinedione. *Arzneimittelforschung, 62*(11), 532-536.

MK Ibrahim, AA Abd-Elrahman, RRA Ayyad, K El-Adl and AM Mansour, et al. (2013). Design and synthesis of some novel 2-(3-methyl-2-oxoquinoxalin-1 (2H)-yl)-N-(4-(substituted) phenyl) acetamide derivatives for biological evaluation as anticonvulsant agents. *Bulletin of Faculty of Pharmacy, Cairo University, 51*(1), 101-111.

MK Ibrahim, AEA El-Helby, AH Ghiaty, AH Biomy and AA Abd-El Rahman, et al. (2009). Modeling, Synthesis and Antihyperglycemic Activity of Novel Quinazolinones Containing Sulfonylurea. *J. Biol. **Pharm.** Sci., 7*(1).

MM Khalifa, HM Sakr, A Ibrahim, AM Mansour and RR Ayyad. (2022). Design and synthesis of new benzylidene-quinazolinone hybrids as potential anti-diabetic agents: In vitro α-glucosidase inhibition, and docking studies. *Journal of Molecular Structure, 1250*, 131768.

MMS Al Ward, AE Abdallah, MF Zayed, RR Ayyad and MA El-Zahabi. (2024). Design, synthesis and biological evaluation of newly triazolo-quinoxaline based potential immunomodulatory anticancer molecules. *Journal of Molecular Structure, 1298*, 137041.

R Ayyad, H Sakr and A Gaafer. (2022). Design and Synthesis of New Compounds Derived from Phenyl Hydrazine and Different Aldehydes as Anticancer Agents. *International Journal of Organic Chemistry, 12*(1), 28-39.

R Ayyad. (2012). Synthesis and Biological Evaluation of Novel Iodophthalazinedione Derivatives as Anticonvulsant Agents. *Al-Azhar Journal of Pharmaceutical Sciences, 45*(1), 1-13.

R Ayyad. (2014). Synthesis and Anticonvulsant Activity of 6-Iodo Phthalazinedione Derivatives. *Al-Azhar Journal of Pharmaceutical Sciences, 50*(2), 43-54.

RA Ayyad, HM Sakr and KM El-Gamal. (n.d.). Design, Synthesis, Computer Modeling and Analgesic Activity of Some New Disubstituted Quinazolin-4 (3H)-ones. *Med. Chem., 6*(5), 299-305.

RR Ayyad, AM Mansour, AM Nejm, YAA Hassan and AR Ayyad. (2024). Stereo Selectivity of Histaminic Receptors Play an Important Role of Anti-histaminic Activity. *Current Research in Medical Sciences, 3*(1), 10-17.

RR Ayyad, AM Mansour, AM Nejm, YAA Hassan, and AR Ayyad. (2025). Esterification of Many Drugs Causes Its Prolonged Action Due to Increase Lipid Solubility and Store in Fatty Tissues. *Current Research in Medical Sciences, 4*(2), 10-15.

RR Ayyad, AM Nejm and AR Ayyad. (2023). The Activity of Some Antibiotics Depend on Stereochemistry of Them (Its Structure). *Journal of Progress in Engineering and Physical Science, 2*(2), 5-7.

RR Ayyad, AM Nejm and AR Ayyad. (2023). The Isomers of Some Drugs One Effective and the Other is Toxic or Ineffective. *Current Research in Medical Sciences, 2*(2), 58-62.

RR Ayyad, AM Nejm, ELT Elbahat, AM Elnagar and MA Aljazar, et al. (2023). The Configuration of Some Hormonal Compounds Play an Important Role in Pharmacological Action (Agonist, Antagonist, Active, More Active). *Journal of Progress in Engineering and Physical, 2*(3).

RR Ayyad, AM Nejm, YAA Hassan and AR Ayyad, et al. (2024). Repair of Destroyed Liver Cells or Protection Liver Cells from

Destruction by Silymarin and Minor Concentration of Vitamin E and Vitamin K. *Journal of Progress in Engineering and Physical*.

RR Ayyad, AM Nejm, YAA Hassan and AR Ayyad. (2023). Mechanism of Action of Many Drugs Depend on Enzyme Inhibition. *Current Research in Medical Sciences, 2*(4), 1-9.

RR Ayyad, AM Nejm, YAA Hassan and AR Ayyad. (2023). The Lipid Solubility of Most Drugs Play Important Role of Its Pharmacological Action and Duration of Action. *Journal of Progress in Engineering and Physical Science, 2*(4), 1-6.

RR Ayyad, HM Sakr, KM El-Gamal, IH Eissa, A HA, AS Tita and FF Sherbini, et al. (2017). Anti-Inflammatory, Proton Pump Inhibitor and Synthesis of Some New Benzimidazole Derivatives. *Der Chemica Sinica, 8*(1), 184-197.

RR Ayyad, YH Abdelaleem and AR Ayyad. (2023). Hydrophobicity, Transport and Target Sites of Action Are Important for the Activity of Many Drugs. *Current Research in Medical Sciences, 2*(3), 15-19.

RRA Ayyad, H Sakr and K El-Gamal. (2016). Synthesis, modeling and anticonvulsant activity of some phthalazinone derivatives. *American Journal of Organic Chemistry, 6*(1), 29-38.

T Al-Warhi, AM El Kerdawy, N Aljaeed, OE Ismael and RR Ayyad, et al. (2020). Synthesis, biological evaluation and in silico studies of certain oxindole–indole conjugates as anticancer CDK inhibitors. *Molecules, 25*(9), 2031.

T Al-Warhi, H Almahli, RM Maklad, ZM Elsayed and MA El Hassab, et al. (2023). 1-Benzyl-5-bromo-3-hydrazonoindolin-2-ones as Novel Anticancer Agents: Synthesis, Biological Evaluation and Molecular Modeling Insights. *Molecules, 28*(7), 3203.

WM Eldehna, MF Abo-Ashour, T Al-Warhi, ST Al-Rashood and A Alharbi, et al. (2021). Development of 2-oxindolin-3-ylidene-indole-3-carbohydrazide derivatives as novel apoptotic and anti-proliferative agents towards colorectal cancer cells. *Journal of Enzyme Inhibition and Medicinal Chemistry, 36*(1), 320-329.

WM Eldehna, R Salem, ZM Elsayed, T Al-Warhi, HR Knany and RR Ayyad, et al. (2021). Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon cancer. *Journal of Enzyme Inhibition and Medicinal Chemistry, 36*(1), 1423-1434.

WM Eldehna, SM Abou-Seri, AM El Kerdawy, RR Ayyad and AM Hamdy, et al. (2016). Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl) phthalazine derivatives. *European Journal of Medicinal Chemistry, 113*, 50-62.